IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant, One Health Advances

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19, Journal of Nanobiotechnology

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant, One Health Advances

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape